The greenwich life/GLSI therapy, GP2, does not treat TNBC.
The greenwich life/GLSI therapy, GP2, does not treat TNBC.
Their treatment is in a immunotherapy administered following surgery in combination with Herceptin for HER2 patients. Phase 2 results indicate 5 year survival improving from 89% on Herceptin alone to nearly 100% with immunotherapy.
The treatment is a peptide that appears to sensitive T cells, which with concurrent administration of GM-CSF, produces a large population of cytotoxic T cells specific to the HER2 protein.
This seems very promising for this subset of breast CA patients, but not helpful for TNBC.
I do not believe, having looked at PRs for last two years, that there has been a BTD filing.
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Revolutionizing Security with Drone Technology Titan Protection and Consulting recently heralded a significant achievement in the field of security technology. The company has introduced a pioneering deployment of self-docking, remote-piloted security drones, which successfully thwarted an attempted theft at a dealership in Kansas City. This event not only underscores...
Continue Reading
Financial Stress — The Silent Productivity Killer Down in the trenches of nine-to-five, it’s money that keeps stealing workers' peace of mind. The TELUS Mental Health Index shines a glaring spotlight on this, revealing that 58% of U.S. workers are most stressed by living costs. Now, that's a kicker when stacking it next to retirement or emergency savings. Those take...
Continue Reading
Equinor Makes a New Oil Discovery in the North Sea Equinor ASA (NYSE: EQNR) is experiencing a positive surge in its stock prices today, following the recent discovery of a new oil field located 17 kilometers from the Troll field in the North Sea. This exciting discovery has estimated reserves that could range between 2 and 12 million barrels of oil equivalent, which...
Continue Reading
Game-Changing Patent for Xact Labs Xact Laboratories just nabbed a new patent—number 12,640,242 if you're keeping track. This isn't just a shiny badge for show; it's core to their play in the big leagues of precision medicine, clinching their spot as a frontrunner in genetic data integration. The endgame here? Tighten that grip on the precision medicine field, and turn...
Continue Reading
Understanding Cleveland-Cliffs' Options Activity Recently, significant investments have been noted in Cleveland-Cliffs, indicating a bullish sentiment among traders. Investors are closely analyzing the options activity for Cleveland-Cliffs (NYSE: CLF), which has revealed a series of intriguing trades. An Overview of Recent Trades Upon reviewing recent options transactions...
Continue Reading
